Abstract | BACKGROUND: MATERIALS AND METHODS: Twenty women were enrolled. All patients received epirubicin 100 mg/m(2) with 5-fluorouracil 500 mg/m(2) and cyclophosphamide 500 mg/m(2) on day 1 and every 21 days thereafter, according to the FEC 100 chemotherapy regimen. Eight patients received a single dose of pegfilgrastim on day 2, while 12 patients were treated with daily administration of lenograstim from days five to ten. Absolute neutrophil count and duration of grade 3-4 neutropenia were monitored using seriated blood samples. The incidence of bone pain was evaluated using the visual analog scale (VAS). RESULTS: CONCLUSION:
|
Authors | Luigi Rossi, Federica Tomao, Giuseppe Lo Russo, Anselmo Papa, Federica Zoratto, Raffaella Marzano, Enrico Basso, Erika Giordani, Monica Verrico, Fabio Ricci, Giulia Pasciuti, Edoardo Francini, Silverio Tomao |
Journal | Therapeutics and clinical risk management
(Ther Clin Risk Manag)
Vol. 9
Pg. 457-62
( 2013)
ISSN: 1176-6336 [Print] New Zealand |
PMID | 24255599
(Publication Type: Journal Article)
|